The Symptoms Didn't Stop When the Drug Did
A man's sexual side effects persisted eight months after he stopped finasteride. The team isn't being asked to prove what caused it — they're being asked how to counsel him honestly about a risk that is officially labeled and genuinely unresolved.
D.K., 42, has been training most mornings for his first marathon since his youngest child started school full-time — a project he describes as "getting a piece of myself back" after a few years of feeling flat. Three years ago he started finasteride 1mg daily for androgenetic alopecia, prescribed by a dermatologist with the standard counseling about reduced libido and possible erectile changes that typically resolve on stopping the drug. He noticed both within the first year, tolerated them, and continued treatment for the hair benefit. Eight months ago he stopped finasteride entirely, expecting the sexual side effects to resolve the way he'd been told they would.
They haven't. His libido remains lower than his pre-treatment baseline by his own clear account, and he has intermittent erectile difficulty he did not have before starting the drug. Standard labs — morning testosterone, thyroid function, fasting glucose — are unremarkable, and he has no history of depression or anxiety before this, no relationship stress he can point to, and no new medications that might independently explain the change. The timeline is the detail that troubles him most: the side effects started while he was still taking the drug, which he expected and accepted, but eight months of complete abstinence from it has not moved the needle at all, which is not what he was told to expect at the time he started. That interval is the point on which his case turns against the label — the 2012 FDA revision to the finasteride labeling added persistent sexual dysfunction continuing after discontinuation, and eight drug-free months puts him well past the window in which the counseling he actually received said this should have resolved. He is otherwise healthy, still running four days a week, and has come in today not asking for a specific treatment but asking, directly, "is this the drug, or is something else wrong with me" — and whether it's safe to try a different hair-loss treatment now that he knows what finasteride did.
What to tell him about a diagnosis that isn't settled
The 2012 label change came from post-marketing case reports and a case-control signal, not a randomized trial — that's hypothesis-generating evidence, not confirmatory. His symptom cluster also has real base rates from ordinary aging, undiagnosed mood changes, and a well-documented nocebo effect once "this drug can do this permanently" enters a patient's awareness. I'd be careful not to tell him this is a known drug effect when the honest answer is that causation remains genuinely unresolved.
I take the methodologic point, but there's a specific, named mechanism behind this, not just a correlation: sustained 5-alpha-reductase inhibition reduces allopregnanolone, a neurosteroid with real effects on mood and sexual function, and there's small clinical and basic-science work supporting a persistent effect in a subset of men. He's reporting a temporally-linked, characteristic, ongoing symptom set. I'd rather name that mechanism directly than let him think we're dismissing it as probably in his head.
Small and basic-science isn't the same standard you'd apply to recommend a treatment change — but it's exactly enough to justify naming a real, labeled possibility to a patient asking directly.
Neither of you actually disagrees about what he should be told — you disagree about how the underlying science will eventually resolve, which isn't the question in front of us today. He asked a direct question and deserves a direct answer: the association is real, is officially labeled, remains scientifically contested on cause, and his symptoms are genuine regardless of which side turns out right. That's counseling, not a verdict, and it's what he actually needs from this visit.
Agreed: document the disputed-causation disclosure explicitly in his chart, give him written information reflecting both the labeled association and the genuine uncertainty about cause, and offer topical minoxidil as a different-mechanism alternative for his hair loss going forward.
Not agreed: whether to refer him for a formal androgen and sexual-function workup to look for an independent cause, or whether the referral itself risks being read by him as confirmation of one side of a still-contested question. The urologist wants the workup for completeness; the primary care physician is wary of how the referral itself will land with a patient who has already been told the science is unsettled.